GENE Genetic Technologies Limited: שווי פעילות לרווח לפני ריבית, מסים ופחת
Genetic Technologies (GENE) leads in preventive diagnostics, offering unique GeneType tests for the early detection of diabetes and oncology. The business relies on a network of advanced laboratories in the US and Australia where genetic data is analyzed. This chart of share prices demonstrates an EV/EBITDA multiple of . Meanwhile, the company strictly adheres to biomaterial disposal regulations and maintains basic office environmental standards.
פילוחים אנליטיים ודוחות נתונים של חברת gtglabs.com (GENE)
The EV/EBITDA multiple determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest. This calculation allows for an assessment of the asset's real value by excluding the impact of debt load and accounting policies. By analyzing the enterprise value to EBITDA ratio of Genetic Technologies (GENE), an investor can evaluate the capital intensity of Genetic Technologies (GENE) in developing predictive genetic tests for early oncology diagnostics.
